Compare Novavax Inc (NVAX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs T Rowe Price Group Inc — how do they compare? Novavax Inc trades at $7.97 (market cap $1.30B), while T Rowe Price Group Inc trades at $116.99 (market cap $24.27B). The key difference: T Rowe Price Group Inc is far larger — about 18.7× Novavax Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TROW | |
|---|---|---|
Market Cap | $1.30B | $24.27B |
Sector | Health | Financials |
52-Week High | $11.19 | $121.68 |
52-Week Low | $6.22 | $86.19 |
Enterprise Value | $879.40M | $21.46B |
Dividend Yield | — | 4.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
